Novo Nordisk Stock Falls After Ozempic Fails to Slow Alzheimer's in Trials. Biogen Jumps.

Core Insights - The drugmaker announced that Ozempic did not demonstrate efficacy in slowing the progression of Alzheimer's disease in two clinical trials [1] Group 1 - The announcement indicates a setback for the drugmaker in its efforts to expand Ozempic's indications beyond diabetes management [1] - The results from the clinical trials may impact investor sentiment and future research directions for the company [1] - The failure of Ozempic in these trials raises questions about the potential of similar drugs in treating neurodegenerative diseases [1]